Extended Data Fig. 9: Ruxolitinib reduces IL-18 and increases plasma cholesterol in individuals with MPN and mice with JAK2^VF mutations.

a, b, Plasma from patients with MPN isolated before and after ruxolitinib (Rux) therapy were analysed for IL-18 (a) and total cholesterol (b; n = 17 patients). c, d, Serum from mice with chimeric 20% Jak2^VF bone marrow was analysed for IL-18 (c) and total cholesterol (d; n = 20 Jak2^VF, n = 22 Jak2^VF + Rux mice). e, Body weight following 12 weeks WTD (n = 19 Jak2^VF, n = 20 Jak2^VF + Rux mice). f–j, Blood counts of WBCs (f), lymphocytes (g), neutrophils (h), monocytes (i) and RBCs (j; n = 18 Jak2^VF, n = 22 Jak2^VF + Rux mice). k, l, Jak2^VF burden in blood neutrophils (k) and monocytes (l; n = 17 Jak2^VF, n = 20 Jak2^VF + Rux mice). m, Representative H&E images of aortic root lesions from mice with 20% Jak2^VF chimeric bone marrow treated with Rux. Dashed lines, necrotic core; scale bars, 200 μm. n, o, Quantification of lesion area (n; n = 17 Jak2^VF, n = 18 Jak2^VF + Rux mice) and percentage necrotic core area (o; n = 18 mice). p, Representative picrosirius red-stained lesions (black lines indicate cap thickness). Scale bars, 200 μm. q, Quantification of cap thickness (n = 18 mice). Mean ± s.e.m.; Wilcoxon paired two-tailed test (a), two-tailed Student’s paired t-test (b); two-tailed Mann–Whitney test (c, e–j, n–p), two-tailed t-test (d), two-way ANOVA followed by Tukey’s post hoc test (k, l).

Source data